MedImmune Signs Cancer Pact with Immunocore - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MedImmune Signs Cancer Pact with Immunocore


p>MedImmune, the biologics R&D arm of AstraZeneca, has entered into a cancer research collaboration with UK-based biotech company Immunocore. Under the terms of the licensing agreement, both companies will conduct research to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. The platform harnesses the patient’s immune system by directing T cells to target and destroy cancerous cells without damaging healthy cells. Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets.

AstraZeneca and MedImmune will have rights to further develop and commercialize ImmTAC products. Immunocore will receive an upfront payment of $20 million per program and is eligible to receive up to $300 million in development and commercial milestone payments for each target program and significant tiered royalties from successful programs.

Source: AstraZeneca

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here